Table 3.
Summary statistic of LY3023414 Cmax and AUCτ in blood in mesothelioma patients following LY3023414 BID administration as monotherapy
| 200 mg Single Dose | 200 mg BID Steady State | ||
|---|---|---|---|
|
Cmax ng/mL |
N | 41 | 28 |
| GeoMean | 846 | 846 | |
| CV% | 85 | 78 | |
| 90% CI | 696–1027 | 677–1058 | |
|
AUCτ ng.h/mL |
N | 22 | 17 |
| GeoMean | 2781 | 2597 | |
| CV% | 51 | 47 | |
| 90% CI | 2329–3320 | 2149–3138 |
AUCτ area under the curve over the dose interval, BID twice daily (every 12 h) dosing interval, τ tau (dosing interval; 12 h for BID dosing, Cmax = maximum observed drug concentration, N number of patients, GeoMean geometric mean, CV coefficient of variation, CI confidence interval around the mean